BPC-157 (10mg vials)
In stock
Peptide Partners
BPC-157 (10mg vials)
Product Format
10mg vials
Vial Size
10mg
Vial Capacity
3 mL
Box Combinations
20mg, 50mg, 100mg, 200mg
Cost per milligram
$3.90 – $5.30
Multi-vial Purity
99.66%
Purity Screening
PASSED
Doubly Validated
YES
Independently Tested
Peptide Partners Manufacturer Id: VI32
Batch Id: BC202604
Research Studies
Study 1: Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
Authors: Chung-Hsun Chang, Wen-Chung Tsai, Ya-Hui Hsu, and Jong-Hwei Su Pang
Source: https://www.mdpi.com/1420-3049/19/11/19066
This in vitro study investigated the effects of BPC 157 on rat Achilles tendon fibroblasts. The researchers found that BPC 157 significantly upregulated the expression of the growth hormone (GH) receptor at both the mRNA and protein levels in a dose- and time-dependent manner. This upregulation of the GH receptor potentiated the proliferative effects of growth hormone, as evidenced by increased cell proliferation (MTT assay) and proliferating cell nuclear antigen (PCNA) expression. Furthermore, the study demonstrated that the addition of growth hormone to BPC 157-treated fibroblasts activated Janus kinase 2 (JAK2), a key downstream signaling molecule in the GH receptor pathway. These findings suggest that BPC 157 promotes tendon healing by enhancing the sensitivity of tendon fibroblasts to growth hormone, thereby amplifying its anabolic effects.
Scientists studied how the peptide BPC-157 affects tendon cells in a lab. They discovered that BPC-157 makes tendon cells more responsive to growth hormone, a natural substance in our bodies that helps with growth and repair. By increasing the number of ‘docking sites’ for growth hormone on the surface of these cells, BPC-157 helps them multiply faster when growth hormone is present. This suggests that BPC-157 could help tendons heal more effectively by boosting the natural healing process driven by growth hormone.
Study 2: Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Authors: Ming-Jer Hsieh, Hsien-Ta Liu, Chao-Nin Wang, Hsiu-Yun Huang, Yuling Lin, Yu-Shien Ko, Jong-Shyan Wang, Vincent Hung-Shu Chang, Jong-Hwei S Pang
Source: https://pubmed.ncbi.nlm.nih.gov/27847966/
This study elucidated the pro-angiogenic mechanism of BPC 157 in vitro and in vivo. In vitro, BPC 157 was shown to increase endothelial tube formation in human umbilical vein endothelial cells (HUVECs). This effect was associated with the upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) expression at both the mRNA and protein levels. BPC 157 also promoted the internalization of VEGFR2, a critical step for receptor activation. The study further demonstrated that BPC 157 time-dependently activated the downstream VEGFR2-Akt-eNOS signaling pathway. Inhibition of endocytosis with dynasore blocked both VEGFR2 internalization and the pro-angiogenic effects of BPC 157, confirming the essential role of this process. These findings indicate that BPC 157 exerts its pro-angiogenic effects by increasing VEGFR2 expression and promoting its internalization and subsequent activation of the VEGFR2-Akt-eNOS signaling cascade.
In this study, scientists investigated how BPC-157 promotes the formation of new blood vessels. They found that in a lab setting, BPC-157 encourages the cells that line blood vessels to form tube-like structures, a key step in creating new vessels. The researchers discovered that BPC-157 achieves this by increasing the number of a specific type of ‘receiver’ (called VEGFR2) on the surface of these cells. It also helps these receivers move inside the cell, which turns on a signaling pathway that tells the cell to start building new blood vessels. This study reveals a key mechanism by which BPC-157 may help with healing and tissue repair by improving blood supply.
Study 3: Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway
Authors: Ming-Jer Hsieh, Cheng-Hung Lee, Ho-Yen Chueh, Gwo-Jyh Chang, Hsiu-Yun Huang, Yuling Lin & Jong-Hwei S. Pang
Source: https://www.nature.com/articles/s41598-020-74022-y
This study investigated the molecular mechanisms by which BPC 157 modulates vasomotor tone. Using isolated rat aorta, the researchers demonstrated that BPC 157 induced a concentration-dependent vasodilation that was endothelium-dependent and mediated by nitric oxide (NO). In vitro experiments with vascular endothelial cells showed that BPC 157 stimulated NO production, which in turn promoted cell migration. The study further elucidated the signaling pathway involved, showing that BPC 157 enhanced the phosphorylation of Src, Caveolin-1 (Cav-1), and endothelial nitric oxide synthase (eNOS). Inhibition of Src abolished these effects, confirming its upstream role. Co-immunoprecipitation analysis revealed that BPC 157 reduced the inhibitory binding between Cav-1 and eNOS, thereby activating eNOS. These findings indicate that BPC 157 modulates vasomotor tone by inducing NO generation through the activation of the Src-Cav-1-eNOS signaling pathway.
In this research, scientists explored how BPC-157 affects the widening of blood vessels. They found that BPC-157 causes blood vessels to relax and widen, and that this effect depends on the inner lining of the blood vessel and a molecule called nitric oxide. In lab experiments, BPC-157 was shown to trigger the production of nitric oxide in the cells lining the blood vessels, which then encourages these cells to move. The study also identified a specific chain of events, or signaling pathway, that BPC-157 activates to produce nitric oxide. By activating this pathway, BPC-157 essentially ‘flips a switch’ that leads to the widening of blood vessels. This could be important for its healing properties, as wider blood vessels can deliver more blood, oxygen, and nutrients to injured tissues.
Storage:
All of our manufacturing partners produce peptides using the Lyophilization (Freeze Drying) process, ensuring products maintain stability for shipping and storage for 12+ months.
In lyophilized form, they are shelf-stable for many weeks. However, for long-term storage, it is recommended to store them in the freezer.
We often hear concerns about the standard “discard after 28 days of first use” disclaimer. Don’t worry, this has nothing to do with studies regarding the efficacy of specific peptides. 28 days is the FDA requirement for producers of multi-use vials to prove their bacteriostatic maintains efficacy. This minimum requirement becomes the de facto standard.
In our experience, if you use proper sterile procedures and refrigerated storage, you can continue sampling from the same reconstituted vial for 3+ months.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
Kisspeptin-10
KSS2607
VI32
2026-07-02
99.71%
Kovera
View File
Reconstitution Solution
BAC202603
WF03
2026-07-13
99.9%
Retatrutide
RTT2613
99.77%
PT-141
PT202605
2026-06-25
99.74%
Tesamorelin
TES202607
2026-06-19
99.80%
TrustPointe
KPV
KV202606
2026-06-12
99.36%
Yes
BPC-157
BC202607
99.82%
Ipamorelin
IP202606
99.98%
Semaglutide
SM202607
99.96%
RTT202606
CJC-1295 ND
CJ202606
2026-06-10
99.88%
RT202607
2026-06-09
99.76%
Tirzepatide
TZ202605
99.55%
99.68%
99.70%
99.34%
99.65%
99.90%
NAD+
NDB202606
2026-05-28
GHK-Cu
CU202605
2026-05-13
99.67%
Epithalon
ET202604
99.86%
5-Amino-1MQ
AM202604
99.78%
2026-05-29
99.53%
Chromate
2026-06-11
99.22%
MOTS-c
MC202605
2026-06-08
99.94%
TB-500 (TB4)
TB202605
TES202605
99.81%
RT202605
2026-05-27
99.75%
BAC202602
2026-05-14
CJC-1295 ND / Ipamorelin
CJIP202605
99.93%
Cagrilintide
CG202607
BPC-157/TB-500
BB202605
99.73%
CU202604
BC202604
99.72%
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin
CIT202604
2026-05-07
TES202604
2026-04-21
99.85%
DSIP
DS202605
KLOW Blend
KW202604
AOD-9604
AO202605
2026-04-20
CG202603
2026-04-14
MC202603
2026-04-04
RT202604
2026-04-16
99.54%
Sermorelin
SER202601
2026-04-01
Pinealon
PN202603
2026-04-03
SS-31
SS202601
Semax
SX202603
2026-03-31
99.91%
RT202603
2026-03-30
99.40%
GLOW Blend
GW202603
2026-03-25
TZ202603
2026-03-27
99.89%
BB202604
99.63%
TES202603
99.52%
2026-03-18
99.60%
Ipamorelin/CJC-1295 (No DAC)
CJIP202602
2026-02-27
99.92%
Thymosin Alpha-1
TA202602
2026-02-25
99.95%
KLOW
KW202602
2026-03-01
NDB202601
2026-02-07
SS202602
2026-02-08
MC202602
2026-02-09
99.41%
Selank
SEK202601
2026-01-29
Unbuffered NAD+
NDU202601
MZ21
2026-01-20
KV202601
IP202601
2026-01-14
TB500 (TB4)
TB202601
RT202602
2026-01-13
PT202512
2026-01-12
BioRegen
SM202601
2026-01-10
CAG202601
99.33%
TES202601
2025-12-29
BP202512
99.46%
BB202512
99.64%
GK202512
SH07
2025-12-19
99.79%
MC202512
2025-12-22
RP260130
SS202512
RP202601
DF05
CJIP202512
2025-12-09
RP202511
RP20251020
2025-11-10
RP20251001
2025-10-13
TZ20250915
2025-10-03
RP20250929
99.47%
Humanin
HP20250805
2025-09-19
YC20250807
99.87%
DS20250820
SY20250806
CJC/Ipamorelin
CI20250805
2025-09-11
99.84%
BP20250808
2025-09-05
99.99%
SM20250723
2025-08-27
TS20250722
2025-08-22
99.10%
CJ20250724
2025-08-20
99.43%
SM20250801
EJ12
IP20250721
2025-08-15
CU20250717
2025-08-09
TZ20250730
2025-08-08
ND20250503
2025-07-31
VIP
VP20250511
99.42%
CD20250708
2025-07-25
BPC/TB500
BB20250630
2025-07-17
TB20250614
Current Endotoxin Certifications
2026-06-30
Conforms
2026-06-22
2026-06-15
2026-05-18
2026-03-26
CJC-1295 ND/Ipamorelin
2026-03-17
TA202601
2026-01-28
TB500
2026-01-07
2026-01-06
2025-12-30
2025-12-08
2025-09-03
Bacteriostatic Water
BAC20250807
2025-08-11
2025-08-04
2025-07-29
2025-07-24
Current Heavy Metal Certifications
2026-07-01
2026-06-26
2026-06-13
2026-06-05
TB-500
2026-05-26
2026-05-24
2026-05-16
2026-04-26
2026-04-22
2026-05-05
2026-04-24
2026-04-02
2026-03-29
2026-01-26
2026-01-19
2026-01-08
2025-12-03
2025-11-24
2025-11-12
Current Sterility Certifications
Pass
2026-06-23
-
2026-04-12
BAC202601
2025-09-09
Meta-Z
MZR20250713
2025-08-26
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
USP <85> Bacterial Endotoxin Result: <x.xx EU/mLBecause it’s reported as “<x.xx” this indicates the test did not detect endotoxin above the detection limit of the cartridge.
If a result is above the limit of detection of the cartridge, it will be reported as a number (without the “<“).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
CV stands for coefficient of variation, a measure of repeatability.
For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
This refers to the precision of the positive control (spiked sample).
Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
This tells us how much of the known endotoxin spike was recovered from your sample.
The acceptable range is 50–200% per USP <85>
Thank you for choosing Peptide Partners.
NOTICE: All information provided above is strictly intended for educational and informational purposes. Our products are designed for research use solely and are not approved for human consumption. Please refrain from any form of ingestion.
By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals. Our products are exclusively intended for laboratory research purposes.
It is imperative that only qualified and licensed professionals handle this product. Under no circumstances should it be utilized as a drug, agricultural or pesticide product, food additive, or household chemical. Misrepresentation of this product for such purposes is strictly prohibited by law. All content on our website is provided for educational use exclusively. Any form of introduction into the human or animal body is illegal.